New Muscle In The Fight Against DMD

New Muscle In The Fight Against DMD

New Muscle In The Fight Against DMD Last week’s biotech headlines lit up with the FDA’s unexpected approval of Sarepta Therapeutics’ (Cambridge, MA) newest Duchenne muscular dystrophy (DMD) drug, Vyondys 53. The FDA changed course after rejecting the product in August...